DexCom, Inc. (DXCM) PB Ratio: 10.07
Is DexCom, Inc.’s P/B ratio high or low?
DexCom, Inc.'s P/B ratio of 10.07 is 47% below its 5-year average of 18.93, near the low end of its 5-year range (7.70–32.80).
The P/B ratio for DexCom, Inc. (DXCM) is 10.07. It is below its 12-month average by 7.67% (10.91).
DXCM PB Ratio Chart
DXCM Average PB Ratio Chart
DXCM Current vs Average PB Ratio Chart
DXCM PB Ratio Metrics
PB RATIO
10.07
PB RATIO AVG TTM
10.91
PB RATIO AVG 3Y
16.29
PB RATIO AVG 5Y
18.93
PB RATIO AVG 10Y
20.87
PB RATIO AVG 15Y
21.80
PB RATIO AVG 20Y
22.29
CURRENT VS TTM AVG
-7.67%
CURRENT VS 3Y AVG
-38.18%
CURRENT VS 5Y AVG
-46.80%
CURRENT VS 10Y AVG
-51.75%
CURRENT VS 15Y AVG
-53.81%
CURRENT VS 20Y AVG
-54.82%
DXCM Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | — | 10.07 | 10.91 | 16.29 | 18.93 |
| Biogen Inc. (BIIB) | $29.00B | 1.56 | 1.34 | 1.77 | 2.40 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 5.01 | 5.40 | 5.98 | 6.64 |
| Veeva Systems Inc. (VEEV) | $27.37B | 3.81 | 5.86 | 6.76 | 9.03 |
| Centene Corporation (CNC) | $31.94B | 1.50 | 0.87 | 1.21 | 1.41 |
| Zoetis Inc. (ZTS) | $34.20B | 10.65 | 12.98 | 15.22 | 16.74 |
| Waters Corporation (WAT) | $23.83B | 1.97 | 8.28 | 13.92 | 32.36 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | N/A | 1966.63 | 623.56 | 375.27 |
| BioNTech SE (BNTX) | $21.81B | 1.01 | 1.14 | 1.16 | 2.48 |
| Agilent Technologies, Inc. (A) | $38.26B | 5.40 | 5.57 | 6.12 | 6.99 |
P/B vs. its own history
At 10.07, P/B is cheaper than usual — richer than 15% of its 20-year range.
20-year low
3.12
median
20.19
20-year high
196.59
Book Value Analysis
P/B Ratio
10.07
Market Price / Book Value per Share
DexCom, Inc. PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. PB Ratio FAQ
- What is the P/B ratio for DexCom, Inc. (DXCM)?
- The P/B ratio for DXCM stock is 10.07.
- Is DexCom, Inc.'s P/B ratio high or low?
- DexCom, Inc.'s P/B ratio of 10.07 is 47% below its 5-year average of 18.93, near the low end of its 5-year range (7.70–32.80).
- What is the TTM average P/B ratio for DexCom, Inc. (DXCM)?
- The TTM average P/B ratio for DXCM stock is 10.91.
- What is the 3Y average P/B ratio for DexCom, Inc. (DXCM)?
- The 3Y average P/B ratio for DXCM stock is 16.29.
- What is the 5Y average P/B ratio for DexCom, Inc. (DXCM)?
- The 5Y average P/B ratio for DXCM stock is 18.93.
- What is the 10Y average P/B ratio for DexCom, Inc. (DXCM)?
- The 10Y average P/B ratio for DXCM stock is 20.87.
- What is the 15Y average P/B ratio for DexCom, Inc. (DXCM)?
- The 15Y average P/B ratio for DXCM stock is 21.80.
- What is the 20Y average P/B ratio for DexCom, Inc. (DXCM)?
- The 20Y average P/B ratio for DXCM stock is 22.29.
DexCom, Inc. PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-10 | 10.07 |
| 2026-06-09 | 10.41 |
| 2026-06-08 | 10.20 |
| 2026-06-05 | 9.70 |
| 2026-06-04 | 9.66 |
| 2026-06-03 | 9.69 |
| 2026-06-02 | 9.78 |
| 2026-06-01 | 9.97 |
| 2026-05-29 | 9.82 |
| 2026-05-28 | 9.63 |
| 2026-05-27 | 9.35 |
| 2026-05-26 | 9.59 |
| 2026-05-22 | 9.60 |
| 2026-05-21 | 9.57 |
| 2026-05-20 | 9.51 |
| 2026-05-19 | 8.91 |
| 2026-05-18 | 8.66 |
| 2026-05-15 | 8.20 |
| 2026-05-14 | 7.70 |
| 2026-05-13 | 7.80 |
| 2026-05-12 | 8.14 |
| 2026-05-11 | 7.90 |
| 2026-05-08 | 8.07 |
| 2026-05-07 | 8.11 |
| 2026-05-06 | 8.03 |
| 2026-05-05 | 7.92 |
| 2026-05-04 | 7.99 |
| 2026-05-01 | 8.17 |
| 2026-04-30 | 7.93 |
| 2026-04-29 | 8.36 |
| 2026-04-28 | 8.62 |
| 2026-04-27 | 8.92 |
| 2026-04-24 | 8.94 |
| 2026-04-23 | 9.11 |
| 2026-04-22 | 9.21 |
| 2026-04-21 | 9.09 |
| 2026-04-20 | 9.39 |
| 2026-04-17 | 9.29 |
| 2026-04-16 | 8.89 |
| 2026-04-15 | 8.94 |
| 2026-04-14 | 9.14 |
| 2026-04-13 | 9.17 |
| 2026-04-10 | 9.30 |
| 2026-04-09 | 9.54 |
| 2026-04-08 | 9.56 |
| 2026-04-07 | 9.17 |
| 2026-04-06 | 9.18 |
| 2026-04-02 | 9.04 |
| 2026-04-01 | 9.06 |
| 2026-03-31 | 9.12 |
| 2026-03-30 | 8.99 |
| 2026-03-27 | 9.04 |
| 2026-03-26 | 9.60 |
| 2026-03-25 | 9.71 |
| 2026-03-24 | 9.67 |
| 2026-03-23 | 9.58 |
| 2026-03-20 | 9.73 |
| 2026-03-19 | 9.77 |
| 2026-03-18 | 9.83 |
| 2026-03-17 | 9.78 |
| 2026-03-16 | 9.64 |
| 2026-03-13 | 9.33 |
| 2026-03-12 | 9.48 |
| 2026-03-11 | 9.63 |
| 2026-03-10 | 9.85 |
| 2026-03-09 | 9.99 |
| 2026-03-06 | 9.89 |
| 2026-03-05 | 10.27 |
| 2026-03-04 | 10.59 |
| 2026-03-03 | 10.62 |
| 2026-03-02 | 10.72 |
| 2026-02-27 | 10.67 |
| 2026-02-26 | 10.80 |
| 2026-02-25 | 10.63 |
| 2026-02-24 | 10.62 |
| 2026-02-23 | 10.64 |
| 2026-02-20 | 10.62 |
| 2026-02-19 | 10.50 |
| 2026-02-18 | 10.58 |
| 2026-02-17 | 10.23 |
| 2026-02-13 | 10.17 |
| 2026-02-12 | 9.45 |
| 2026-02-11 | 10.18 |
| 2026-02-10 | 10.19 |
| 2026-02-09 | 10.49 |
| 2026-02-06 | 10.46 |
| 2026-02-05 | 10.44 |
| 2026-02-04 | 10.58 |
| 2026-02-03 | 10.70 |
| 2026-02-02 | 10.84 |
| 2026-01-30 | 10.92 |
| 2026-01-29 | 11.06 |
| 2026-01-28 | 10.96 |
| 2026-01-27 | 11.01 |
| 2026-01-26 | 10.96 |
| 2026-01-23 | 10.89 |
| 2026-01-22 | 11.05 |
| 2026-01-21 | 10.78 |
| 2026-01-20 | 10.57 |
| 2026-01-16 | 10.39 |
| 2026-01-15 | 10.35 |
| 2026-01-14 | 10.42 |
| 2026-01-13 | 10.50 |
| 2026-01-12 | 10.61 |
| 2026-01-09 | 10.07 |
| 2026-01-08 | 10.23 |
| 2026-01-07 | 10.48 |
| 2026-01-06 | 10.44 |
| 2026-01-05 | 10.11 |
| 2026-01-02 | 9.94 |
| 2025-12-31 | 9.92 |
| 2025-12-30 | 10.02 |
| 2025-12-29 | 10.08 |
| 2025-12-26 | 10.10 |
| 2025-12-24 | 10.08 |
| 2025-12-23 | 9.99 |
| 2025-12-22 | 10.08 |
| 2025-12-19 | 9.87 |
| 2025-12-18 | 9.85 |
| 2025-12-17 | 9.83 |
| 2025-12-16 | 9.92 |
| 2025-12-15 | 9.82 |
| 2025-12-12 | 10.01 |
| 2025-12-11 | 10.30 |
| 2025-12-10 | 10.10 |
| 2025-12-09 | 9.91 |
| 2025-12-08 | 9.81 |
| 2025-12-05 | 9.79 |
| 2025-12-04 | 9.75 |
| 2025-12-03 | 9.69 |
| 2025-12-02 | 9.63 |
| 2025-12-01 | 9.49 |
| 2025-11-28 | 9.49 |
| 2025-11-26 | 9.34 |
| 2025-11-25 | 9.22 |
| 2025-11-24 | 9.30 |
| 2025-11-21 | 9.00 |
| 2025-11-20 | 8.73 |
| 2025-11-19 | 8.93 |
| 2025-11-18 | 8.99 |
| 2025-11-17 | 8.74 |
| 2025-11-14 | 8.68 |
| 2025-11-13 | 8.92 |
| 2025-11-12 | 8.91 |
| 2025-11-11 | 8.69 |
| 2025-11-10 | 8.20 |
| 2025-11-07 | 8.22 |
| 2025-11-06 | 8.67 |
| 2025-11-05 | 8.86 |
| 2025-11-04 | 9.14 |
| 2025-11-03 | 9.03 |
| 2025-10-31 | 8.70 |
| 2025-10-30 | 10.19 |
| 2025-10-29 | 10.82 |
| 2025-10-28 | 10.98 |
| 2025-10-27 | 11.20 |
| 2025-10-24 | 11.16 |
| 2025-10-23 | 11.27 |
| 2025-10-22 | 11.22 |
| 2025-10-21 | 11.07 |
| 2025-10-20 | 10.86 |
| 2025-10-17 | 10.57 |
| 2025-10-16 | 10.52 |
| 2025-10-15 | 10.38 |
| 2025-10-14 | 10.50 |
| 2025-10-13 | 10.34 |
| 2025-10-10 | 10.33 |
| 2025-10-09 | 10.80 |
| 2025-10-08 | 10.75 |
| 2025-10-07 | 10.48 |
| 2025-10-06 | 10.53 |
| 2025-10-03 | 10.64 |
| 2025-10-02 | 10.54 |
| 2025-10-01 | 10.48 |
| 2025-09-30 | 10.67 |
| 2025-09-29 | 10.54 |
| 2025-09-26 | 10.64 |
| 2025-09-25 | 10.84 |
| 2025-09-24 | 10.71 |
| 2025-09-23 | 10.82 |
| 2025-09-22 | 11.03 |
| 2025-09-19 | 10.70 |
| 2025-09-18 | 12.02 |
| 2025-09-17 | 12.13 |
| 2025-09-16 | 12.14 |
| 2025-09-15 | 11.99 |
| 2025-09-12 | 12.09 |
| 2025-09-11 | 12.06 |
| 2025-09-10 | 12.06 |
| 2025-09-09 | 12.44 |
| 2025-09-08 | 12.37 |
| 2025-09-05 | 12.77 |
| 2025-09-04 | 12.81 |
| 2025-09-03 | 12.52 |
| 2025-09-02 | 11.79 |
| 2025-08-29 | 11.95 |
| 2025-08-28 | 11.91 |
| 2025-08-27 | 12.12 |
| 2025-08-26 | 12.08 |
| 2025-08-25 | 12.05 |
| 2025-08-22 | 13.05 |
| 2025-08-21 | 12.79 |
| 2025-08-20 | 12.96 |
| 2025-08-19 | 12.83 |
| 2025-08-18 | 12.82 |
| 2025-08-15 | 12.84 |
| 2025-08-14 | 12.68 |
| 2025-08-13 | 12.68 |
| 2025-08-12 | 12.72 |
| 2025-08-11 | 12.35 |
| 2025-08-08 | 12.51 |
| 2025-08-07 | 12.12 |
| 2025-08-06 | 12.12 |
| 2025-08-05 | 11.97 |
| 2025-08-04 | 12.10 |
| 2025-08-01 | 12.58 |
| 2025-07-31 | 12.81 |
| 2025-07-30 | 14.13 |
| 2025-07-29 | 16.06 |
| 2025-07-28 | 16.10 |
| 2025-07-25 | 16.00 |
| 2025-07-24 | 15.59 |
| 2025-07-23 | 15.54 |
| 2025-07-22 | 15.30 |
| 2025-07-21 | 15.11 |
| 2025-07-18 | 15.08 |
| 2025-07-17 | 15.12 |
| 2025-07-16 | 15.13 |
| 2025-07-15 | 15.24 |
| 2025-07-14 | 15.34 |
| 2025-07-11 | 14.99 |
| 2025-07-10 | 15.36 |
| 2025-07-09 | 15.26 |
| 2025-07-08 | 15.06 |
| 2025-07-07 | 14.91 |
| 2025-07-03 | 14.91 |
| 2025-07-02 | 15.03 |
| 2025-07-01 | 15.03 |
| 2025-06-30 | 15.69 |
| 2025-06-27 | 15.52 |
| 2025-06-26 | 15.29 |
| 2025-06-25 | 15.22 |
| 2025-06-24 | 15.74 |
| 2025-06-23 | 14.35 |
| 2025-06-20 | 14.38 |
| 2025-06-18 | 14.56 |
| 2025-06-17 | 14.71 |
| 2025-06-16 | 14.92 |
| 2025-06-13 | 14.74 |
| 2025-06-12 | 14.90 |
| 2025-06-11 | 14.92 |
| 2025-06-10 | 15.25 |
| 2025-06-09 | 15.40 |
| 2025-06-06 | 15.58 |
| 2025-06-05 | 15.41 |
| 2025-06-04 | 15.39 |
| 2025-06-03 | 15.60 |
| 2025-06-02 | 15.37 |
| 2025-05-30 | 15.43 |
| 2025-05-29 | 15.26 |
Showing the most recent 260 of 4,657 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach